Bouvel Investment Partners’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-15,901
Closed -$2.04M 78
2023
Q2
$2.04M Buy
15,901
+367
+2% +$44.4K 1.12% 43
2023
Q1
$1.8M Buy
15,534
+442
+3% +$49.5K 1.05% 41
2022
Q4
$1.71M Buy
15,092
+480
+3% +$52.7K 1.1% 38
2022
Q3
$1.18M Buy
14,612
+140
+1% +$11.9K 0.78% 49
2022
Q2
$1.08M Buy
14,472
+216
+2% +$19.7K 0.81% 49
2022
Q1
$1.82M Buy
14,256
+132
+0.9% +$14.4K 1.11% 43
2021
Q4
$1.9M Sell
14,124
-336
-2% -$48.3K 1.06% 42
2021
Q3
$1.98M Sell
14,460
-284
-2% -$35.8K 1.12% 45
2021
Q2
$1.57M Buy
14,744
+32
+0.2% +$3.07K 0.89% 54
2021
Q1
$1.32M Sell
14,712
-56
-0.4% -$5.26K 0.85% 52
2020
Q4
$1.36M Buy
+14,768
New +$1.32M 0.97% 50

Other funds holding DXCM

Bouvel Investment Partners's DXCM Position: Q3 2023 in Review

Bouvel Investment Partners sold out of DexCom (DXCM) in Q3 2023, closing a stake of 15,901 shares — an estimated $2.04M sold.

Bouvel Investment Partners first reported a position in DXCM in Q4 2020 and held it in 11 quarters. The position peaked at $2.04M in Q2 2023. 903 funds tracked by Wall St. Rank hold DXCM as of Q3 2023.

  • Bouvel Investment Partners reported no remaining DexCom position as of Q3 2023 after selling out during the quarter.
  • Bouvel Investment Partners sold 15,901 DexCom shares in Q3 2023, an estimated $2.04M.
  • Bouvel Investment Partners first reported a position in DexCom in Q4 2020 and held it in 11 quarters.
  • Bouvel Investment Partners's DexCom position peaked at $2.04M in Q2 2023.
  • 903 funds tracked by Wall St. Rank held DexCom as of Q3 2023.

Based on Bouvel Investment Partners's 13F filing for Q3 2023, filed 11 Oct 2023.